NRXP 1D - Swing Position - Not reco to buy/sell
Extreme volatility has been seen consistently in the bio-sectors as seen the chart in the above analysis - NXRP has received consistently positive news regarding their primary drug ZYESAMI and the clinical trials they are actively participating in.
Profile :
NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behaviour. The company was founded in 2015 and is based in Wilmington, Delaware.
GLTA!!
Extreme volatility has been seen consistently in the bio-sectors as seen the chart in the above analysis - NXRP has received consistently positive news regarding their primary drug ZYESAMI and the clinical trials they are actively participating in.
Profile :
NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behaviour. The company was founded in 2015 and is based in Wilmington, Delaware.
GLTA!!